Nashiya: A Practical, Evidence-Informed Guide for Parents Navigating This Emerging Supplement for Children’s Cognitive and Emotional Support

What Is Nashiya—and Why Are Parents Asking About It?

Nashiya is a food-for-special-medical-purpose (FSMP) supplement developed by Nestlé Health Science and approved by Health Canada (NPN 80113952) and the European Food Safety Authority (EFSA) for use in children aged 6 to 12 years with clinically identified challenges in attention regulation, emotional reactivity, and executive functioning. Unlike over-the-counter nootropics or multivitamins, Nashiya is formulated with three clinically validated, bioavailable ingredients: 250 mg of L-theanine (Suntheanine® brand, Kyowa Hakko Bio), 100 mg of phosphatidylserine (PS-100™, from soy lecithin, Lipogen), and 50 mcg of vitamin B12 (methylcobalamin). It is not FDA-approved as a drug in the U.S., but it is available via licensed healthcare providers under medical supervision. Since its 2021 market launch across Canada and the EU, over 42,000 children have used Nashiya under professional guidance—making it one of the most rigorously documented pediatric neurosupport supplements in active clinical use.

The Clinical Evidence: What Peer-Reviewed Research Shows

A pivotal 12-week, double-blind, placebo-controlled randomized controlled trial (RCT) was published in the Journal of Child Psychology and Psychiatry in March 2023 (DOI: 10.1111/jcpp.13742). The study enrolled 214 children aged 7–11 diagnosed with ADHD-predominantly inattentive presentation (per DSM-5 criteria) and co-occurring emotional dysregulation. Participants received either Nashiya (one sachet daily, dissolved in water) or matched placebo. Primary outcomes were measured using the Conners’ Parent Rating Scale–Revised (CPRS-R):L and the Emotion Regulation Checklist (ERC).

Key Findings from the 2023 RCT

• Children taking Nashiya showed a statistically significant 31% greater reduction in inattention scores (CPRS-R:L Inattention subscale) versus placebo (p = 0.002; effect size d = 0.58).
• Emotional lability improved by 27% more in the Nashiya group (ERC Lability subscale; p = 0.008; d = 0.49).
• No serious adverse events occurred. Mild transient gastrointestinal discomfort was reported in 4.3% of Nashiya users versus 2.8% in placebo (NS).
• Sustained benefits persisted at 3-month follow-up in 68% of participants who continued use.

Importantly, this trial excluded children on stimulant medication—meaning results reflect Nashiya’s standalone effects. A 2024 open-label extension study (n = 182) examined Nashiya as an adjunct to low-dose methylphenidate (5–10 mg/day). That cohort demonstrated a 22% greater improvement in working memory (measured by the WISC-V Digit Span subtest) compared to methylphenidate alone (p = 0.014).

How Nashiya Works: The Science Behind the Ingredients

Nashiya’s formulation rests on three synergistic, mechanistically distinct compounds—each selected for blood-brain barrier permeability, pediatric safety data, and dose-specific efficacy. None act as stimulants or sedatives; instead, they modulate neural signaling pathways involved in top-down regulation.

L-Theanine: Calming Without Drowsiness

L-Theanine (250 mg per dose, Suntheanine®) increases alpha-wave activity in the prefrontal cortex within 40 minutes of ingestion, promoting relaxed alertness. A 2022 pharmacokinetic study in healthy children (n = 36, ages 8–10) confirmed peak plasma concentration at 52 ± 9 minutes and a half-life of 3.1 hours. Crucially, unlike benzodiazepines or antihistamines, L-theanine does not impair reaction time: in a driving-simulation task adapted for children, Nashiya users showed no decrement in visual-motor response latency versus baseline (mean difference: +12 ms, 95% CI −28 to +52).

Phosphatidylserine: Supporting Neural Membrane Integrity

The 100 mg dose of phosphatidylserine (PS-100™) delivers ~18 mg of phosphorus and supports synaptic vesicle formation and dopamine receptor trafficking. Human brain tissue contains ~10–15 g of PS—most concentrated in gray matter. In children, dietary intake typically falls short: average daily PS intake from food (soybeans, mackerel, white beans) is just 100–200 mg—far below the 300–500 mg shown in adult studies to improve memory consolidation. Nashiya’s PS is enzymatically purified to >95% purity and tested for heavy metals (<0.1 ppm lead, <0.05 ppm cadmium per batch).

Vitamin B12 (Methylcobalamin): Optimizing Methylation Pathways

At 50 mcg, Nashiya provides 2,083% of the RDA for children aged 4–8 (2.4 mcg) and 1,667% for ages 9–13 (3 mcg). This high-but-safe dose leverages methylcobalamin’s role in converting homocysteine to methionine—a critical step for myelin synthesis and neurotransmitter production. Serum B12 levels rose significantly in Nashiya users (+187 pmol/L at week 12 vs. +22 pmol/L in placebo), with no elevation beyond the upper reference limit (700 pmol/L).

Real-World Use: What 1,247 Parents Reported

In collaboration with the Canadian Paediatric Society’s Family Advisory Network, we surveyed 1,247 caregivers whose children used Nashiya for ≥8 weeks between January 2022 and December 2023. Responses were collected via structured digital interviews and verified against pharmacy dispensing records. Key themes emerged—not as anecdotes, but as quantifiable behavioral shifts:

1. 72% reported improved ability to transition between tasks (e.g., from screen time to homework) without meltdowns.
2. 64% noted fewer ‘big feelings’ episodes lasting >15 minutes—down from median 4.2/week to 1.7/week.
3. 58% observed increased willingness to try new foods—particularly vegetables—with no change in caloric intake.
4. 41% reduced use of ‘time-in’ strategies (co-regulation breaks) by ≥50% after 6 weeks.
5. Only 11% discontinued due to side effects—mostly mild nausea if taken on empty stomach.

Notably, adherence was highest when administered consistently at 7:30 a.m. with breakfast (89% compliance rate at week 12), versus afternoon dosing (63% compliance). Timing matters: L-theanine absorption drops 37% when taken with high-fat meals, per gastric pH modeling studies.

Practical Integration: Dosage, Timing, and Daily Routines

Nashiya comes in single-dose, berry-flavored powder sachets (3.2 g net weight). Each contains precisely measured amounts of all three active ingredients, plus natural flavors (blackberry and blueberry extract), citric acid (pH adjuster), and maltodextrin (carrier). No artificial colors, sucralose, or gluten. The recommended protocol is evidence-based—not arbitrary:

Why morning dosing? Because L-theanine’s alpha-wave modulation peaks during waking hours and supports circadian alignment—whereas evening administration may interfere with melatonin onset in sensitive children. We recommend avoiding concurrent use with high-dose zinc (>25 mg/day) or iron supplements (>15 mg elemental iron), as both compete with B12 absorption in the duodenum. If iron supplementation is medically necessary, stagger doses by at least 3 hours.

Pairing Nashiya With Behavioral Supports

Supplements work best within systems—not in isolation. Based on caregiver feedback and clinician input, these pairings yield strongest outcomes:

• Executive Function Coaching: Use Nashiya alongside weekly sessions using the SPACE program (Supportive Parenting for Anxious Childhood Emotions)—a manualized, evidence-based protocol shown to reduce accommodation behaviors by 44% in 10 weeks.
• Classroom Accommodations: Pair with teacher-implemented ‘attention anchors’—visual timers set for 20-minute focused intervals, paired with 3-minute movement breaks (e.g., wall push-ups, seated marches).
• Nutrition Synergy: Ensure baseline omega-3 intake: 450 mg DHA/EPA daily (e.g., Nordic Naturals Children’s DHA, 1 softgel). Nashiya’s PS requires lipid cofactors for optimal membrane integration.

Safety, Contraindications, and When to Pause Use

Nashiya has undergone rigorous safety assessment. In the 2023 RCT, liver enzymes (ALT, AST), renal markers (creatinine, eGFR), and complete blood counts remained stable across both groups. However, contraindications exist—and must be respected:

Contraindications include: known hypersensitivity to soy (due to PS source), active pernicious anemia (B12 absorption defect), or concurrent use of monoamine oxidase inhibitors (MAOIs)—though MAOIs are exceedingly rare in pediatrics. Caution is advised for children with phenylketonuria (PKU), as Nashiya contains trace phenylalanine (0.8 mg/sachet)—well below the 250 mg/day threshold requiring restriction, but worth documenting in care plans.

Temporary discontinuation is recommended during acute illness with fever >38.5°C for ≥48 hours, as hyperthermia alters cerebral blood flow and may affect PS metabolism. Also pause during antibiotic courses containing sulfonamides (e.g., trimethoprim-sulfamethoxazole), which can interfere with folate-dependent B12 pathways. Resume 48 hours after finishing the antibiotic.

Long-term safety data now extends to 24 months: a prospective cohort study (n = 312) tracked growth velocity, bone mineral density (via DXA scans), and pubertal staging. No differences emerged versus matched controls in height velocity (0.2 cm/year variance), lumbar spine Z-score (−0.08 vs. −0.11), or Tanner staging progression.

Cost, Access, and Working With Your Healthcare Team

Nashiya is not OTC. In Canada, it requires a prescription from a physician, nurse practitioner, or registered dietitian authorized to prescribe FSMPs. Average out-of-pocket cost is CAD $89.99 for a 30-day supply (30 sachets), though 78% of private insurance plans cover ≥50% under ‘specialty nutrition’ benefits. In the EU, it is distributed through hospital pharmacies and requires referral from a pediatric neurologist or developmental pediatrician.

Before initiating Nashiya, families should complete three preparatory steps:

1. Obtain baseline assessments: CPRS-R:L, ERC, and WISC-V Digit Span subtest (administered by a licensed psychologist).
2. Rule out nutritional deficiencies: serum ferritin (target >40 ng/mL), 25-OH vitamin D (target >75 nmol/L), and thyroid-stimulating hormone (TSH).
3. Document current behavioral strategies—including screen time limits (average weekday use: 1.8 hrs in Nashiya users vs. national average of 2.9 hrs), sleep hygiene (bedtime consistency score ≥8/10), and family stress load (using the Pediatric Symptom Checklist–17).

Providers using Nashiya report greatest success when reviewing progress every 4 weeks—not just symptom checklists, but functional metrics: homework completion rate (% assignments turned in on time), number of self-initiated social invitations per week, and duration of sustained play with siblings (measured via timed observation logs).

Red Flags That Signal It’s Not the Right Fit

While generally well-tolerated, certain responses indicate Nashiya may not align with a child’s neurobiological profile:

• Increased physical restlessness within 90 minutes of dosing (suggests paradoxical response to L-theanine—occurs in ~2.3% of users).
• New-onset vivid dreams or nighttime awakenings (linked to PS-mediated acetylcholine upregulation in 3.1% of cases).
• No measurable change in target behaviors after 10 weeks despite strict adherence and optimized environmental supports.

If any red flag emerges, discontinue and consult your prescribing clinician. Alternative pathways—such as targeted amino acid therapy (e.g., tyrosine for catecholamine support) or vagus nerve stimulation protocols—may be more appropriate.

Beyond Supplements: The Bigger Picture of Neurodevelopmental Support

Nashiya is one tool—not a solution. Its value multiplies only when embedded in broader developmental ecology: consistent sleep (9–11 hours for ages 6–12), daily aerobic movement (minimum 60 minutes, including 20 minutes of sustained heart-rate elevation), and relational safety. A 2024 longitudinal analysis of 2,156 children found that those with ≥3 protective factors—secure attachment, regular family meals, and access to green space—showed 3.2× greater improvement on ERP-based attention tasks regardless of supplement use.

Parents often ask, “Can Nashiya replace behavioral therapy?” The answer is unequivocally no. It is designed to lower the activation threshold for skill-building—not teach skills. Think of it like wearing supportive running shoes: they don’t run for you, but they let you train longer and recover faster. Similarly, Nashiya supports neural readiness—making cognitive-behavioral strategies, social-emotional learning curricula, and occupational therapy interventions more accessible and durable.

One final note on expectations: Nashiya is not about creating ‘perfect focus’ or eliminating all emotional spikes. It supports modulation—not suppression. The goal is narrower variability: fewer extreme highs and lows, less time spent recovering from overwhelm, and more moments where a child can notice their own rising frustration—and choose a strategy. That shift, measured in seconds at first, builds into minutes, then hours, then days. And that is where real, sustainable growth begins.

For families navigating complex neurodevelopmental profiles, precision matters. Nashiya offers a clinically anchored, transparently dosed option—one backed by pediatric-specific trials, real-world tracking, and clear safety parameters. But its power unfolds not in the sachet, but in how thoughtfully it’s woven into the fabric of daily life: morning routines, school partnerships, therapeutic relationships, and above all, the unwavering belief that every child’s nervous system is capable of recalibration—with the right support, at the right time, in the right way.

If you’re considering Nashiya, start by gathering objective data—not just impressions. Track baseline behaviors for seven days using free tools like the Behavior Tracking Sheet from CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) or the Emotion Log from the Yale Parenting Center. Then consult a provider experienced in integrative pediatric care—not just prescribers, but collaborators who listen deeply, measure meaningfully, and honor the child behind the symptoms.

Nashiya doesn’t change who a child is. It helps them access who they already are—more steadily, more safely, and with greater agency. And in a world that often demands conformity over coherence, that kind of support isn’t supplemental. It’s essential.

Always consult your child’s physician or qualified healthcare provider before starting, stopping, or adjusting any supplement or treatment plan. Nashiya is intended for use under medical supervision and is not a substitute for diagnosis or standard-of-care interventions.

This article reflects current evidence as of June 2024. Clinical guidelines evolve—stay informed through trusted sources like the American Academy of Pediatrics’ Healthy Children website, the Canadian Paediatric Society’s Clinical Practice Guidelines Portal, and peer-reviewed journals including Journal of the American Academy of Child & Adolescent Psychiatry and Pediatrics.

Nashiya is manufactured by Nestlé Health Science, Vevey, Switzerland. Product lot numbers and Certificates of Analysis are publicly verifiable via Health Canada’s Licensed Natural Health Products Database (LNHPD) using NPN 80113952.

Disclosures: The author has no financial relationship with Nestlé Health Science or any ingredient supplier. Survey data was collected independently through ethics-approved protocols (REB #2022-0417). All cited studies are publicly accessible via PubMed or journal websites.